February 9, 2021 – Akston Biosciences Completes Second Licensing and Supply Agreement with Dechra Pharmaceuticals PLC
Akston Biosciences Corporation and Dechra Pharmaceuticals PLC today announced the signing of a licensing and supply agreement for the co-development and commercialization of AKS-425c, a once-a-week, injectable insulin therapy for the treatment of diabetes in cats. The companies expect development to be completed within five years and receive marketing authorizations in the U.S., European Union, and other global markets. The supply agreement calls for Akston to be the exclusive manufacturer of the product to be marketed by Dechra. The multi-million-dollar licensing and development agreement includes payments to Akston on signing, for development milestones, and a royalty on sales. In 2019, the two companies concluded a similar licensing and supply agreement for AKS-321d, a once-a-week insulin therapy for dogs.
Click here to view the full press release.